On December 14, 2021, AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a research collaboration with the University of California, Irvine (UCI) to explore the therapeutic potential of exosomes and other extracellular vesicles (EVs) produced by neural stem cells derived from AgeX pluripotent stem cells, with the goal of developing therapies to treat adverse neurocognitive effects of cancer chemotherapy and radiation therapy on brain function. This research project seeks to address a critical unmet medical need that impacts the quality of life for millions of cancer survivors. The agreement between AgeX and UCI has been handled by the team at UCI Beall Applied Innovation.